Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
March 10 2025 - 3:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ Preliminary
Proxy Statement
☐ Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐ Definitive
Proxy Statement
☒ Definitive
Additional Materials
☐ Soliciting
Material Under § 240.14a–12
PharmaCyte Biotech,
Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other
than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
☒ No
fee required
☐ Fee
paid previously with preliminary materials
☐ Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Feb 2025 to Mar 2025
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Mar 2024 to Mar 2025